Exiqon A/S enters into a definitive agreement to acquire Oncotech, Inc. and enters the market for cancer molecular diagnostics


EXIQON ENTERS INTO A DEFINITIVE AGREEMENT TO ACCQUIRE ONCOTECH INC AND ENTERS   
THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS                                     

Summary: Exiqon A/S (OMX: EXQ) has entered into a final and definitive agreement
under which Exiqon will acquire California-based Oncotech Inc., a leading       
supplier of extreme drug resistance diagnostic tests in cancer. The merger of   
the two companies will create a world leader in molecular diagnostic products   
based on miRNA.

Attachments

announcement 1-2008.pdf